Intellia Therapeutics (NTLA) Change in Accured Expenses (2015 - 2026)

Intellia Therapeutics (NTLA) has 12 years of Change in Accured Expenses data on file, last reported at -$11.9 million in Q1 2026.

• Change in Accured Expenses for Q1 2026 came in at -$11.9 million, up 17.12% year-over-year; the trailing twelve-month figure through Mar 2026 was -$2.8 million (down 17.04% YoY), and the FY2025 annual result was -$5.3 million, up 49.23% from the prior year.
• Change in Accured Expenses eased to -$11.9 million in Q1 2026 per NTLA's latest filing, from $9.0 million in the prior quarter.
• Over five years, Change in Accured Expenses peaked at $13.6 million in Q3 2022 and troughed at -$22.4 million in Q1 2024.
• A 5-year average of -$332529.4 and a median of $3.0 million in 2022 frame the typical range for Change in Accured Expenses.
• The sharpest annual moves came in 2022 and 2023: Change in Accured Expenses jumped 220.06% in 2022, then sank 367.9% in 2023.
• A 5-year view of Change in Accured Expenses shows it stood at $3.1 million in 2022, then surged by 194.01% to $9.0 million in 2023, then plunged by 56.23% to $4.0 million in 2024, then surged by 128.36% to $9.0 million in 2025, then slumped by 232.35% to -$11.9 million in 2026.
• Business Quant data shows NTLA's Change in Accured Expenses at -$11.9 million in Q1 2026, $9.0 million in Q4 2025, and -$715000.0 in Q3 2025.